Posted on 11/26/2021 9:08:27 PM PST by SeekAndFind
Nov 26 (Reuters) - Novavax Inc (NVAX.O) said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.
The company's COVID-19 shot contains an actual version of the virus' spike protein that cannot cause disease but can trigger the immune system. The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529.
"The initial work will take a few weeks," a company spokesperson said. Shares of the company closed up nearly 9% on Friday.
Novavax's vaccine received its first emergency use approval earlier this month in Indonesia followed by the Philippines.
The company has said it is on track to file for U.S. approval by the end of the year. It has also filed for approvals with the European Medicines Agency as well as in Canada.
Other vaccine developers, including Germany's BioNTech SE (22UAy.DE) and Johnson & Johnson (JNJ.N), have said they are testing the effectiveness of their shots against the new variant, which is named Omicron by the World Health Organisation. read more
Inovio Pharmaceuticals Inc (INO.O)said it had begun testing its vaccine candidate, INO-4800, to evaluate its effectiveness against the new variant. The company expects the testing to take about two weeks.
Inovio also said it was simultaneously designing a new vaccine candidate that specifically targeted Omicron.
"Best case scenario, INO-4800 ... will be completely resilient against omicron, but if that's not the case then we will have a newly designed vaccine ready to go if need be," said Kate Broderick, senior vice president of Inovio's R&D division.
(Excerpt) Read more at reuters.com ...
Simple Death JAB Expansion.
Novavax Developing Vaccine Against Variant That Appeared 72 Hours Ago – Will Be Ready in Two Weeks, Already in Emergency Use Trials in Indonesia and Phillipines
November 26, 2021 | Sundance | 53 Comments
Wow, 72 hours ago no one even heard the name Omicron variant. Now, in less than three days, a variant has been identified, global travel has been halted, states of emergency have been declared, and now we see a pharmaceutical company announcing the variant specific vaccine trial that will begin in the U.S. in a few weeks. This government relationship with Big Pharma is certainly generating some fast action, eh?
If a person was cynically inclined; while knowing governments’ need to control inflation yet cannot raise interest rates or stop purchasing debt because current legislative spending continues – a remarkable control option would be to halt demand; and a person might think this was suspicious, or something.
http://theconservativetreehouse.com/
At least it isn’t the same shot from the version of COVID-19 from two years ago, in China.
All the boosters have been the old shot, all over again.
Let's motivate Mother Nature to create even MORE deadly variants of the spike protein!
Funny. The medical community just had to skip “Xi” in the Greek alphabet and jump from Nu to Omicron.
Begs the question of where is the vax for aids or Ebola or cancer or common cold and all the much older maladies that have plagued mankind for so long? Anyone else think “how convenient timing”? It’s almost as if these big pharms and science community and government knew about it in advance.
It’s all effing bs. Only idiots can’t see through this manure. Good lord 90% of Americans are retards!
Seems like it was planned. Of course there will be fools pushing in line wanting the newest vaxx
💉😷🐂💨💩💸
Wasn’t it just discovered leas than a week ago?
The government ordered and prepaid for untold millions if not billions of doses of the old Chicom virus vaccine. Guess that’s all garbage now and the pharms and politicians that got their kickbacks can order those mansions now.
Goes back to November 11th:
https://www.dw.com/en/covid-what-we-know-about-the-omicron-variant/a-59948143
The long shot [Novavax Covid Vaccine]
sciencemag.org ^ | 06 Nov 2020: | Meredith Wadman
Posted on 6/15/2021, 11:38:33 PM by ransomnote
Novavax's vaccine is made of tiny particles studded with the coronavirus spike protein plus honeycomblike molecules, derived from plants, that stimulate the immune system.
Image of Novavax's tiny particles studded with coronavirus spike proteins
Eighteen months ago, a small vaccinemaker here called Novavax faced an existential threat: delisting by the NASDAQ stock index. On the heels of a second failed vaccine trial in less than 3 years, the firm's shares had plunged to less than $1 for 30 straight days, triggering a warning by NASDAQ. Frantic to conserve cash, the company sold its two Maryland manufacturing facilities, slicing its payroll by more than 100 employees. By January, it employed only 166 people.
“Good ideas. Bad management. … The company will probably die soon,” a former Novavax manager wrote on Glassdoor.com in October 2019.
Very perceptive.
Leaky vaccines lead to Marek’s Disease in chickens.
https://en.wikipedia.org/wiki/Marek‘s_disease
We are playing with fire here!
Sure they are.
Yeah, go team! Does this count at the first or second booster in covid vaccine bingo? :-/
I predicted a 2nd booster by May or June of 2022.
Guess that will be a little late.
After all, a new booster will be needed for the 27-plus variants that will come...
(Only idiots can’t see through this manure)
You could have just written “dedicated and true believers in CNN and MSNBC”
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.
